Navigation Links
Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA)
Date:3/15/2012

(IPF) is a progressive, debilitating and ultimately fatal disease characterized predominantly by fibrosis (scarring) in the lungs, hindering the ability for gas exchange in the lungs. IPF is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity.  The median survival time from diagnosis is two to five years, which makes IPF more rapidly lethal than many cancers, including breast, ovarian and colorectal.  Published epidemiology studies suggest there is a range of between 85,000 and 141,000 IPF patients in Europe, with approximately 113,000 being the median estimate.  Patients diagnosed with IPF are primarily between the ages of 40 and 80, with a median age of 63 years. The disease tends to affect slightly more men than women.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and orphan fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exch
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
2. New Data Demonstrate Longer-Term Safety Profile of Esbriet®
3. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
4. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
5. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
6. New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses
7. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
8. Thera Max® Cold and Flu Brand Receives Great Benefits from Its Ongoing Social Media Marketing Awareness Program
9. Sleep Breathing Machine Shows Clear Benefits in Children with Sleep Apnea
10. Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors
11. Recent Study Reveals Benefits to Women From DHEA Hormone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 UBM Medica US ... a new online community and information resource for neurologists ... and treat their patients with neurological disorders . ... an aging population, necessitates greater access to dedicated information ... statistics on neurological conditions include: , 1 ...
(Date:7/23/2014)... July 23, 2014 Research and Markets ... (ECG) Market by Product, End-user & by Lead Type ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... into three major segments, namely, holter monitor, resting, and ... valued at $3,683 million in 2013 and is poised ...
(Date:7/23/2014)... -- The Centers for Medicare & Medicaid Services (CMS) ... Organization (QIN-QIO) contract to a partnership led by the ... 1, WVMI will launch Quality Insights Quality Innovation Network ... Pennsylvania , Delaware , ... will engage providers and the community in multiple, data-driven ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
... June 29 Max Neeman International, India ,s ... extended the platform to provide expert CDISC (Clinical Data Interchange Standards ... data conversion, implementation of CDISC standards and CDISC compliance checks. , ... CDISC SDTM (Standard ...
... IRVINE, Calif. , June 29 Avrio Biopharmaceuticals, ... of David A. Gelber as the Director of Manufacturing. ... production systems and ensuring clients receive high quality service in a ... , ...
Cached Medicine Technology:Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model 2Avrio Appoints David L. Gelber to Director of Manufacturing 2Avrio Appoints David L. Gelber to Director of Manufacturing 3
(Date:7/23/2014)... 23, 2014 The next episode of ... Milwaukee, Wis. who was physically fit through childhood and ... ultimately made the heart-wrenching decision to give her son ... the past 18 years, and she punished herself by ... Featuring a unique, non-competitive approach to weight loss transformations, ...
(Date:7/23/2014)... Calgary, AB (PRWEB) July 23, 2014 ... provider of in-home care for seniors, is proud to ... Webinar Series featuring experts in a wide range of ... licensed clinical social worker and award-winning author Nancy Kriseman, ... stress and ways to prevent burnout by becoming more ...
(Date:7/23/2014)... or itchy skin lesions could be a warning sign ... multiple lesions that are suspicious looking, and those that ... non-melanoma skin cancers," study author Dr. Gil Yosipovitch, chairman ... in a Temple University Health System news release. ... who were confirmed to have skin cancer lesions between ...
(Date:7/23/2014)... study supports a growing body of research suggesting ... hormones in treating postmenopausal breast cancer, with fewer ... with standard anti-hormone therapies. The study will be ... journal Reproductive Biology and Endocrinology . , ... in women in the United States. Approximately 70% ...
(Date:7/23/2014)... The National Institute of Biomedical Imaging and Bioengineering will ... on July 30, 2014 on the NIH campus. There ... covering a wide breadth of NIBIB-funded research. , ... Harvard, Engineering Microbial Rhodopsins as Optical Voltage Sensor, ... Labeled Probes for Nerve Imaging during ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5
... effect in an ostrich farm, after fears ... of nearly sixty ostriches//. The agriculture ... of veterinarians and labs that detected the ... ,To much relief, this avian influenza strain ...
... has woken up after a stroke to find that her Geordie ... of accent//. ,Lynda Walker, 60, is the victim of ... regained consciousness after a stroke in March last year to find ... accent. ,Ms Walker said: “I got very down about ...
... year diploma courses in Yoga and Naturopathy as well ... at Kurukshetra. ,The syllabus for the ... courses would help in promotion of Yoga, Naturopathy and ... ,She said with a view to integrate allopathic ...
... of bird flu evolving into a more transmissible agent in ... H5N1 virus in poultry and the continued exposure to humans ... agency. ,The overall case-fatality rate was 56 per cent ... years, according to the study by the World Health Organisation ...
... An analysis of Caucasian Americans and people with more education ... obesity //and anxiety disorders. ,Scientists from Group Health ... risk of getting anxiety and mood disorders in obese than ... July issue of the Archives of General Psychiatry, found that ...
... revealed that nearly half of the women, who received ... suicide. ,Women given cognitive behavioral therapy were ... treated by expert therapists - said Marsha Linehan, lead ... the women who received the treatment called dialectical behavior ...
Cached Medicine News:Health News:Obesity, a Reflector of Mental Health – Study Find 2Health News:Obesity, a Reflector of Mental Health – Study Find 3Health News:Special Behavioral Therapies made Women more likely to Attempt Suicide 2Health News:Special Behavioral Therapies made Women more likely to Attempt Suicide 3
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Each slide contains a gram positive control of Staphylococcus aureus ATCC ® 25923 and a gram negative control of Escherichia coli ATCC ® 25922....
Each slide contains an A.F.B. positive staining control of Mycobacterium scrofulaceum ATCC ® 19981 in simulated sputum and an A.F.B. negative staining control of Escherichia coli ATCC ® 25922...
... The Equalizer With 384 Well Plate Capability ... features of the original Equalizerexpandable and equal tip ... and in-lab calibration capabilities. In addition, this model ... to 4.5mm for loading and accessing many gels ...
Medicine Products: